Changeflow GovPing Pharma & Drug Safety EPO Patent Publication: Anti-Folate Receptor Al...
Routine Notice Added Final

EPO Patent Publication: Anti-Folate Receptor Alpha Antibodies

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office has published patent application EP4499697A1 concerning anti-folate receptor alpha antibodies and their methods of use. The application was filed by Zymeworks BC Inc. and lists multiple inventors. This publication is part of the standard patent application process.

What changed

The European Patent Office (EPO) has published patent application EP4499697A1, titled 'Anti-Folate Receptor Alpha Antibodies and Methods of Use'. This publication, dated March 18, 2026, details a new antibody technology developed by Zymeworks BC Inc. The application includes extensive inventor lists and International Patent Classification (IPC) codes related to antibodies, pharmaceutical compositions, and their use in treating cancer.

This publication represents a step in the patenting process for Zymeworks BC Inc. and does not impose any new regulatory obligations on pharmaceutical companies or healthcare providers. Compliance officers should note this as a development in the intellectual property landscape for antibody-based therapeutics, particularly those targeting folate receptor alpha, which may be relevant for competitive intelligence or future licensing considerations.

Source document (simplified)

← EPO Patent Bulletin

ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE

Publication EP4499697A1 Kind: A1 Mar 18, 2026

Applicants

Zymeworks BC Inc.

Inventors

RICH, James R., DAVIES, Rupert H., BARNSCHER, Stuart Daniel, UROSEV, Dunja, KANG, Sukhbir Singh, CHAN, Peter Wing Yiu, DAS, Samir, HERNANDEZ ROJAS, Andrea, GENE, Robert William, YOUNG, Ada G. H., LAWN, Samuel Oliver, CHUI, Danny, BROWMAN, Duncan, CLAVETTE, Brandon

IPC Classifications

C07K 16/28 20060101AFI20260209BHEP A61K 39/395 20060101ALI20260209BHEP A61K 47/68 20170101ALI20260209BHEP A61P 35/00 20060101ALI20260209BHEP C12N 15/13 20060101ALI20260209BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4499697A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Patent Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.